Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
The board of the South-Eastern Norway Regional Health Authority (Helse Sør-Øst) has distributed financial resources to new research projects for 2015. Of the in total 551 incoming applications 105 new projects were granted support (19.1%). The competition was especially hard in the category "open project support", where 12 projects got full backing.
A substantial amount of the resources are given to young researchers. Support is given to 52 doctoral and 38 post doctoral stipendiates, as well as to four researcher grants and three career grants. The latter category is for young outstandig researchers planning to establish an independent research group. Oslo University Hospital accounts for about 75% of the research in the region.
Section for Cellular Therapy, Department of Cancer Treatment, Oslo University Hospital receives 9.6 mill NOK through the BIOTEK2021 program and 7,0 mill NOK in the FORNY2020 program from The Norwegian Research Council. The project receiving 9.6 mill NOK is entitled “Personalized Immunotherapy: Re-targeting T cells against Cancer”, and was one of five within biomedical research to receive funding.
The project supported by the FORNY2020 program is entitled "Dendritic cell immunotherapy for glioblastoma (DEN-STEM)" and is led by Iver A. Langmoen, head of the Vilhelm Magnus Laboratory and the research team at Section for Cellular Therapy. The project aims to develop a novel therapeutic cancer vaccine against brain tumours.
Per Morten Sandset, head physician and head of research at the Department of Haematolgoy at the Divison of Cancer Medicine, Surgery and Transplantation, has recently written for the Oslo University Hospital research blog. Here, he conveys the opinion that the preferences of the patients must be given more attention. Many years as a practicing physician has led him to the conclusion that patients should be more involved in decisions concerning assessment and treatment of their own diseases.
Meza-Zepeda and Myklebost co-author recent Cancer Cell publication on the architecture and evolution of cancer neochromosomes
Leonardo A. Meza-Zepeda and Ola Myklebost in collaboration with David M. Thomas’ group in Australia co-author an article recently published in Cancer Cell (journal impact factor 23.89), entitled “The Architecture and Evolution of Cancer Neochromosomes”.
This article describes for the first time, at single base resolution, the architecture of cancer-associated neochromosomes in well- and dedifferentiated liposarcomas.
The Institute Seminar on Wednesday 10th of December will ble held by Arne Yndestad from the Research Institute of Internal Medicine at Oslo University Hospital - Rikshospitalet. Title of his talk: “Metaflammation in the pathogenesis of disease”
Time and place: 12:00 in the Auditorium, New research building, Montebello.
Stein Kvaløy, head physician and head of research at the Divison of Cancer Medicine, Surgery and Transplantation, has recently contributed to the new popular scientific Oslo University Hospital research blog.
Kvaløy writes about the hospital's commitment to proton therapy - a type of radiation treatment that uses protons rather than x-rays to treat cancer.
Dec 8, 2014
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
An ER clamp for endosome fission
EMBO J (in press)
eEF2K-a new target in breast cancers with combined inactivation of p53 and PTEN
EMBO Mol Med, 6 (12), 1512-4
Antiretroviral treatment initiation
Lancet Infect Dis, 14 (12), 1175
More selected publications